GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Novo Nordisk AS (NEOE:NVON) » Definitions » 1-Year Sharpe Ratio

Novo Nordisk AS (NEOE:NVON) 1-Year Sharpe Ratio : N/A (As of Apr. 25, 2025)


View and export this data going back to 2025. Start your Free Trial

What is Novo Nordisk AS 1-Year Sharpe Ratio?

The 1-Year Sharpe Ratio measures the additional return that an investor receives per unit of increase in risk over the past year. As of today (2025-04-25), Novo Nordisk AS's 1-Year Sharpe Ratio is Not available.


Competitive Comparison of Novo Nordisk AS's 1-Year Sharpe Ratio

For the Drug Manufacturers - General subindustry, Novo Nordisk AS's 1-Year Sharpe Ratio, along with its competitors' market caps and 1-Year Sharpe Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Novo Nordisk AS's 1-Year Sharpe Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Novo Nordisk AS's 1-Year Sharpe Ratio distribution charts can be found below:

* The bar in red indicates where Novo Nordisk AS's 1-Year Sharpe Ratio falls into.


;
;

Novo Nordisk AS 1-Year Sharpe Ratio Calculation

The 1-Year Sharpe Ratio measures the performance of an investment such as a stock or portfolio compared to a risk-free asset. A stock / portfolio's 1-Year Sharpe Ratio can be calculated by dividing the difference between the one-year returns of the investment and the risk-free rate, by the standard deviation of the investment returns over one year.


Novo Nordisk AS  (NEOE:NVON) 1-Year Sharpe Ratio Explanation

The 1-Year Sharpe Ratio inidicates the risk-adjusted return of an investment over the past year. It is calculated as the annualized result of the average monthly excess return divided by its standard deviation over the past year. The monthly excess return is the monthly investment return minus the monthly risk-free rate (typically the 10-year Treasury Constant Maturity Rate). If the risk-free rate for a specific region is not available, U.S. data is used by default.

The greater a portfolio's Sharpe Ratio, the better its risk-adjusted performance. A negative Sharpe Ratio means the risk-free rate is greater than the portfolio’s historical or projected return, or else the portfolio's return is expected to be negative.


Novo Nordisk AS 1-Year Sharpe Ratio Related Terms

Thank you for viewing the detailed overview of Novo Nordisk AS's 1-Year Sharpe Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Novo Nordisk AS Business Description

Address
Novo Alle 1, Bagsvaerd, DNK, 2880
With roughly one third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (constituting less than 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.

Novo Nordisk AS Headlines

No Headlines